Literature DB >> 16194204

Factor VIIa binding and internalization in hepatocytes.

G Hjortoe1, B B Sorensen, L C Petersen, L V M Rao.   

Abstract

The liver is believed to be the primary clearance organ for coagulation proteases, including factor VIIa (FVIIa). However, at present, clearance mechanisms for FVIIa in liver are unknown. To obtain information on the FVIIa clearance mechanism, we investigated the binding and internalization of FVIIa in liver cells using a human hepatoma cell line (HEPG2), and primary rat and human hepatocytes as cell models. 125I-FVIIa bound to HEPG2 cells in a time- and dose-dependent manner. Anti-tissue factor antibodies reduced the binding by about 25%, whereas 50-fold molar excess of unlabeled FVIIa had no effect. HEPG2 cells internalized FVIIa with a rate of 10 fmol 10(-5) cells h(-1). In contrast to HEPG2 cells, FVIIa binding to primary rat hepatocytes was completely independent of TF, and excess unlabeled FVIIa partly reduced the binding of 125I-FVIIa to rat hepatocytes. Further, compared with HEPG2 cells, three- to fourfold more FVIIa bound to rat primary hepatocytes, and the bound FVIIa was internalized at a faster rate. Similar FVIIa binding and internalization profiles were observed in primary human hepatocytes. Plasma inhibitors had no effect on FVIIa binding and internalization in hepatocytes. In contrast, annexin V, which binds to phosphatidylserine, blocked the binding and internalization. Consistent with this, binding of gla-domain-deleted FVIIa to hepatocytes was markedly diminished. In summary, the data presented herein reveal differences between HEPG2 cells and primary liver cells in FVIIa binding and internalization, and suggest that the rapid turnover of membrane and not a receptor-mediated endocytosis may be responsible for internalization of FVII/FVIIa in primary hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16194204      PMCID: PMC1266294          DOI: 10.1111/j.1538-7836.2005.01542.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  31 in total

1.  Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody.

Authors:  R A Fleck; L V Rao; S I Rapaport; N Varki
Journal:  Thromb Res       Date:  1990-07-15       Impact factor: 3.944

2.  Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site.

Authors:  J F McDonald; A M Shah; R A Schwalbe; W Kisiel; B Dahlbäck; G L Nelsestuen
Journal:  Biochemistry       Date:  1997-04-29       Impact factor: 3.162

3.  Effect of heparin on in vivo turnover of clotting factor.

Authors:  R HASSELBACK; P F HJORT
Journal:  J Appl Physiol       Date:  1960-09       Impact factor: 3.531

Review 4.  Regulation of coagulation by a multivalent Kunitz-type inhibitor.

Authors:  G J Broze; T J Girard; W F Novotny
Journal:  Biochemistry       Date:  1990-08-21       Impact factor: 3.162

5.  Internalization and degradation of recombinant human coagulation factor VIIa by the human hepatoma cell line HuH7.

Authors:  G T Chang; W Kisiel
Journal:  Thromb Haemost       Date:  1995-02       Impact factor: 5.249

6.  Distribution of the recombinant coagulation factor 125I-rFVIIa in rats.

Authors:  T L Beeby; L F Chasseaud; T Taylor; M K Thomsen
Journal:  Thromb Haemost       Date:  1993-09-01       Impact factor: 5.249

7.  Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces.

Authors:  D T Le; S I Rapaport; L V Rao
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

8.  Lysine-based cluster mannosides that inhibit ligand binding to the human mannose receptor at nanomolar concentration.

Authors:  E A Biessen; F Noorman; M E van Teijlingen; J Kuiper; M Barrett-Bergshoeff; M K Bijsterbosch; D C Rijken; T J van Berkel
Journal:  J Biol Chem       Date:  1996-11-08       Impact factor: 5.157

9.  Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa.

Authors:  L V Rao; S I Rapaport; A D Hoang
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

10.  Pharmacokinetics of recombinant factor VIIa in the rat--a comparison of bio-, immuno- and isotope assays.

Authors:  M K Thomsen; V Diness; P Nilsson; S N Rasmussen; T Taylor; U Hedner
Journal:  Thromb Haemost       Date:  1993-09-01       Impact factor: 5.249

View more
  5 in total

1.  Tanshinone IIA sodium sulfonate facilitates endocytic HMGB1 uptake.

Authors:  Yusong Zhang; Wei Li; Shu Zhu; Arvin Jundoria; Jianhua Li; Huan Yang; Saijun Fan; Ping Wang; Kevin J Tracey; Andrew E Sama; Haichao Wang
Journal:  Biochem Pharmacol       Date:  2012-09-26       Impact factor: 5.858

2.  Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients.

Authors:  H Agersø; D F Brophy; H Pelzer; E J Martin; M Carr; U Hedner; M Ezban
Journal:  J Thromb Haemost       Date:  2011-02       Impact factor: 5.824

3.  Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium.

Authors:  Samit Ghosh; Usha R Pendurthi; Anne Steinoe; Charles T Esmon; L Vijaya Mohan Rao
Journal:  J Biol Chem       Date:  2007-02-27       Impact factor: 5.157

4.  Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa).

Authors:  R Gopalakrishnan; U Hedner; S Ghosh; R C Nayak; T C Allen; U R Pendurthi; L V M Rao
Journal:  J Thromb Haemost       Date:  2009-11-23       Impact factor: 5.824

5.  Overview of the human pharmacokinetics of recombinant activated factor VII.

Authors:  Thomas Klitgaard; Tina G Nielsen
Journal:  Br J Clin Pharmacol       Date:  2007-10-24       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.